Cue Biopharma (CUE) Profit After Tax (2017 - 2025)

Cue Biopharma has reported Profit After Tax for 9 years, with the latest figure at $1.6 million in Q4 2025.

• Quarterly Profit After Tax rose 116.68% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.6 million (up 34.59% YoY) and the FY2025 annual result came in at -$26.6 million, up 34.6% from the prior year.
• Profit After Tax rose to $1.6 million in Q4 2025 per CUE's latest filing, from -$7.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at $1.6 million in Q4 2025 and troughed at -$14.6 million in Q4 2022.
• A 5-year average of -$10.8 million and a median of -$11.6 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 74.09% in 2022, then surged 116.68% in 2025.
• Over 5 years, Profit After Tax stood at -$8.4 million in 2021, then slumped by 74.09% to -$14.6 million in 2022, then grew by 7.96% to -$13.4 million in 2023, then grew by 29.31% to -$9.5 million in 2024, then jumped by 116.68% to $1.6 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered $1.6 million, -$7.4 million, and -$8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.